PPA
LPCN icon

Parametric Portfolio Associates’s Lipocine LPCN Stock Holding History

Parametric Portfolio Associates’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-843
Closed -$49K – 3950
2017
Q4 		$49K Sell
843
-180
-18% -$11.2K ﹤0.01% 3871
2017
Q3 		$69K Sell
1,023
-52
-5% -$3.76K ﹤0.01% 3977
2017
Q2 		$73K Sell
1,075
-2,380
-69% -$155K ﹤0.01% 3945
2017
Q1 		$229K Buy
3,455
+736
+27% +$47.7K ﹤0.01% 3547
2016
Q4 		$170K Buy
2,719
+413
+18% +$26.1K ﹤0.01% 3625
2016
Q3 		$175K Buy
+2,306
New +$143K ﹤0.01% 3604
2016
Q2 		– Sell
-1,783
Closed -$308K – 3897
2016
Q1 		$308K Buy
+1,783
New +$304K ﹤0.01% 3588

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Parametric Portfolio Associates's LPCN Position: Q1 2018 in Review

Parametric Portfolio Associates sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 843 shares — an estimated $49K sold.

Parametric Portfolio Associates first reported a position in LPCN in Q1 2016 and held it in 7 quarters. The position peaked at $308K in Q1 2016. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

  • Parametric Portfolio Associates reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
  • Parametric Portfolio Associates sold 843 Lipocine shares in Q1 2018, an estimated $49K.
  • Parametric Portfolio Associates first reported a position in Lipocine in Q1 2016 and held it in 7 quarters.
  • Parametric Portfolio Associates's Lipocine position peaked at $308K in Q1 2016.
  • 27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on Parametric Portfolio Associates's 13F filing for Q1 2018, filed 14 May 2018.